Taysha Gene Therapies, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 4.22 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.38B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Details
| Name | Taysha Gene Therapies, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 99 |
| Founded | 2019 |
| Ipo Date | 2020-09-24 |
| Ceo | Sean Nolan |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 20.00 |
| Isin | US8776191061 |
| Cusip | 877619106 |
| Cik | 1806310 |
| Sic | 2836 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Sean P. Nolan | Chief Executive Officer and Chairman |
| Dr. Sukumar Nagendran M.D. | President, Head of Research and Development and Director |
| Kamran Alam CPA, M.B.A. | Chief Financial Officer and Corporate Secretary |
| Hayleigh Collins | Director of Corporate Communications and Investor Relations |
| Michael B. Johannesen | Chief Legal Officer and Corporate Secretary |
| Frederick Porter Ph.D. | Chief of Staff and Technical Operations Officer |
| Emily McGinnis M.P.H. | Chief Patient and External Affairs Officer |
| Sean McAuliffe | Chief Business Officer |
| Dr. Steven Gray Ph.D. | Chief Scientific Advisor of UT Southwestern Gene Therapy Program |
| Berge Minassian M.D. | Chief Medical Advisor of UT Southwestern Gene Therapy Program |
Contact
| Address | 3000 Pegasus Park Drive, Suite 1430, Dallas, Texas 75247, United States |
| Phone | 214 612 0000 |
| Website | https://www.tayshagtx.com |